Lactobacilli and bacteremia in southern Finland, 1989-1992.

Clin Infect Dis

Department of Biochemistry and Food Chemistry, University of Turku, Finland.

Published: March 1996

In order to assess the potential of lactobacilli to cause serious infections, we studied the prevalence of bacteremia due to Lactobacillus species during a 4-year period (1989-1992) in southern Finland, which has a population of about 2.5 million. Among 3,317 blood culture isolates, lactobacilli were identified in eight patients, five of whom had a severe disease predisposing to bacteremic complications. The eight strains isolated were identified to the species level and typed by carbohydrate fermentation tests and by direct sequencing of enzymatically amplified 16S rRNA. The results did not provide evidence that any particular species or subspecies of Lactobacillus was the cause of the infections; no infections caused by isolates similar to the recently introduced dairy probiotic strain, Lactobacillus GG (ATCC 53103), were observed. The data show an infrequent association of lactobacilli with bacteremic infections in spite of the ubiquitous presence of these organisms in the gastrointestinal tract and their widespread consumption in fermented milks; thus, there is strong evidence that their pathogenic potential is very low.

Download full-text PDF

Source
http://dx.doi.org/10.1093/clinids/22.3.564DOI Listing

Publication Analysis

Top Keywords

southern finland
8
lactobacilli
4
lactobacilli bacteremia
4
bacteremia southern
4
finland 1989-1992
4
1989-1992 order
4
order assess
4
assess potential
4
potential lactobacilli
4
lactobacilli serious
4

Similar Publications

The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).

View Article and Find Full Text PDF

Objectives: Affecting one in five adults in Europe, hearing loss (HL) is linked to adverse health outcomes, including dementia. We aim to investigate educational inequalities in hearing health in Europe and how these inequalities change with age, gender, and region.

Methods: Utilizing 2004-2020 data from the Harmonised Survey of Health, Ageing, and Retirement in Europe (SHARE), a representative sample of Europeans aged 50 and above, we analyse: 1) age-standardized prevalence of HL and hearing aid (HA) use among eligible individuals; 2) educational inequalities therein using the Relative Index of Inequality (RII) across age, gender, and European regions.

View Article and Find Full Text PDF

Aim: This study aimed to develop a universally applicable core set of quality indicators for Hirschsprung's disease care through a consensus-driven process, to standardise and improve care quality across Europe.

Methods: A modified Delphi method was used to achieve consensus among healthcare professionals (HPs) and patient representatives (PRs) across Europe. Participants completed three rounds of anonymous surveys, rating quality indicators for Hirschsprung's disease care.

View Article and Find Full Text PDF

Future climate projections are expected to have a substantial impact on boreal lake circulation regimes. Understanding lake sensitivity to warmer climates is therefore critical for mitigating potential ecological and societal impacts. The Holocene Thermal Maximum (HTM; ca 7-5 ka BP) provides a valuable analogue to investigate lake responses to warmer climates devoid of major anthropogenic influences.

View Article and Find Full Text PDF

Communicating scientific evidence: drugs for Alzheimer's disease as a case study.

Curr Med Res Opin

January 2025

Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.

This paper reviews the scientific evidence on new anti-amyloid monoclonal antibodies for treating Alzheimer's disease as a case study for improving scientific evidence communication. We introduce five guidelines condensed from the biomedical evidence literature but adapted to the short format of science communication in e.g.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!